- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Tanuja Chitnis Discusses Research Into Treatments for Pediatric MS
While the community has seen the first clinical trials and first FDA-approved therapy for pediatric multiple sclerosis, it remains challenging to treat, said Tanuja Chitnis, MD, associate neurologist at Brigham and Women’s Hospital and professor of neurology at Harvard Medical School.
While the community has seen the first clinical trials and first FDA-approved therapy for pediatric multiple sclerosis, it remains challenging to treat, said Tanuja Chitnis, MD, associate neurologist at Brigham and Women’s Hospital and professor of neurology at Harvard Medical School.
Transcript
What is the challenge with treating pediatric multiple sclerosis and what research would you like to see done?
So, I think one of the major challenges in treating pediatric MS is the fact that it’s a highly inflammatory disease, and we need safe and effective treatments. And we have seen the launch of the first clinical trials, and in fact, the first FDA-approved treatment for pediatric multiple sclerosis, which was Gilenya, or fingolimod. And that was approved this past year.
And that is through the efforts of multiple centers and clinicians worldwide as well as families participating in clinical trials. And this is really a way to get to the answers in terms of the overall efficacy of various treatments, as well as the safety profile. And we need to understand both in order to best advise our families.
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
